( October 2, 2026, 11:28 AM EDT) -- WASHINGTON, D.C. — Over the objections of one circuit judge, the Federal Circuit U.S. Court of Appeals denied a petition from Eli Lilly and Co. (Lilly) for rehearing en banc and panel rehearing, leaving in place a panel’s April decision to reverse a Massachusetts federal judge’s judgment as a matter of law (JMOL) of invalidity on patents held by Teva Pharmaceuticals International GmbH and its American affiliate for lack of written description and enablement; the denial of rehearing also leaves in place the panel’s decision to reinstate the jury’s verdict....